Jacobs Levy Equity Management Inc. Has $1.02 Million Position in Cardlytics, Inc. (NASDAQ:CDLX)

Jacobs Levy Equity Management Inc. lifted its position in Cardlytics, Inc. (NASDAQ:CDLX) by 56.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 317,644 shares of the company’s stock after acquiring an additional 113,966 shares during the period. Jacobs Levy Equity Management Inc. owned approximately 0.63% of Cardlytics worth $1,016,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Atom Investors LP bought a new stake in Cardlytics in the third quarter valued at approximately $33,000. Canton Hathaway LLC increased its position in shares of Cardlytics by 95.7% in the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after buying an additional 2,200 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Cardlytics during the 3rd quarter worth $45,000. Intech Investment Management LLC bought a new position in Cardlytics during the third quarter worth about $47,000. Finally, BNP Paribas Financial Markets grew its position in shares of Cardlytics by 32.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,745 shares of the company’s stock valued at $63,000 after purchasing an additional 4,796 shares during the period. Institutional investors own 68.10% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on CDLX shares. Evercore ISI assumed coverage on shares of Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 price target on the stock. Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a research note on Thursday, November 7th. Northland Securities cut shares of Cardlytics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $7.00 to $5.00 in a research note on Friday, August 16th. Northland Capmk cut shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Finally, Bank of America cut Cardlytics from a “neutral” rating to an “underperform” rating and decreased their price objective for the company from $4.00 to $3.50 in a report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Cardlytics has a consensus rating of “Hold” and a consensus price target of $6.92.

Insider Buying and Selling at Cardlytics

In related news, CEO Amit Gupta sold 22,607 shares of the company’s stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the transaction, the chief executive officer now directly owns 178,519 shares in the company, valued at approximately $687,298.15. This represents a 11.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Alexis Desieno sold 25,118 shares of the stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $3.43, for a total transaction of $86,154.74. Following the transaction, the chief financial officer now owns 116,481 shares in the company, valued at approximately $399,529.83. The trade was a 17.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 68,691 shares of company stock valued at $237,767 in the last three months. 4.40% of the stock is currently owned by company insiders.

Cardlytics Stock Up 3.1 %

Shares of CDLX stock opened at $3.95 on Monday. Cardlytics, Inc. has a 52-week low of $2.89 and a 52-week high of $20.52. The stock has a market cap of $200.75 million, a price-to-earnings ratio of -0.65 and a beta of 1.53. The firm’s 50-day moving average is $3.83 and its 200-day moving average is $5.57. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The business had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. During the same quarter last year, the firm posted ($0.26) EPS. The company’s quarterly revenue was down 15.1% on a year-over-year basis. Sell-side analysts predict that Cardlytics, Inc. will post -1.52 EPS for the current year.

Cardlytics Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.